Search
Bunamiodyl
go.drugbank.com/drugs/DB04814ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Dantron
go.drugbank.com/drugs/DB04816ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
Oxeladin
go.drugbank.com/drugs/DB04822ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Guanabenz
go.drugbank.com/drugs/DB00629ApprovedWithdrawnGuanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalIt is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigationalToremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative ...
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.
Gentian violet cation
go.drugbank.com/drugs/DB00406ApprovedA dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalThe acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814]. … Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the